WHO Drug Information, Vol. 26, No. 3, 2012
Recommended INN: List 68
International Nonproprietary Names for Pharmaceutical Substances (INN) RECOMMENDED International Nonproprietary Names: List 68 Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–105) and Recommended (1–66) International Nonproprietary Names can be found in Cumulative List No. 14, 2011 (available in CD-ROM only).
Dénominations communes internationales des Substances pharmaceutiques (DCI) Dénominations communes internationales RECOMMANDÉES: Liste 68 Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond. Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie. On trouvera d’autres listes de Dénominations communes internationales proposées (1–105) et recommandées (1–66) dans la Liste récapitulative No. 14, 2011 (disponible sur CD-ROM seulement).
Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI) Denominaciones Comunes Internacionales RECOMENDADAS: Lista 68 De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia. Las listas de Denominaciones Comunes Internacionales Propuestas (1–105) y Recomendadas (1–66) se encuentran reunidas en Cumulative List No. 14, 2011 (disponible sólo en CD-ROM).
301
Recommended INN: List 68
WHO Drug Information, Vol. 26, No. 3, 2012
Latin, English, French, Spanish: Recommended INN DCI Recommandée DCI Recomendada
Chemical name or description; Molecular formula; Graphic formula Nom chimique ou description; Formule brute; Formule développée Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada
acidum deoxycholicum deoxycholic acid acide désoxycholique ácido desoxicólico
3α,12α-dihydroxy-5β-cholan-24-oic acid acide 3α,12α-dihydroxy-5β-cholan-24-oïque ácido 3α,12α-dihidroxi-5β-colan-24-oico C24H40O4 H CH3 H HO H H H3C OH CH3 H H H H CO2H
acidum florilglutamicum ( F) 18 florilglutamic acid ( F) acide florilglutamique ( F) ácido florilglútamico ( F) 18 18
18
(4S)-4-(3-[ F]fluoropropyl)-L-glutamic acid acide (4S)-4-(3-[ F]fluoropropyl)-L-glutamique ácido (4S)-4-(3-[ F]fluoropropil)-L-glutámico C8H14 FNO4 HO2C H H [18F] CO2H NH2 18 18 18
18
acidum tiazoticum tiazotic acid acide tiazotique ácido tiazótico
[(5-methyl-1H-1,2,4-triazol-3-yl)sulfanyl]acetic acid acide [(5-méthyl-1H-1,2,4-triazol-3-yl)sulfanyl]acétique ácido [(5-metil-1H-1,2,4-triazol-3-il)sulfanil]acético C5H7N3O2S HN H3C N N S CO2H
302
WHO Drug Information, Vol. 26, No. 3, 2012
Recommended INN: List 68
amitifadinum amitifadine amitifadine amitifadina
(1R,5S)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane (1R,5S)-1-(3,4-dichlorophényl)-3-azabicyclo[3.1.0]hexane (1R,5S)-1-(3,4-diclorofenil)-3-azabiciclo[3.1.0]hexano C11H11Cl2N H N H Cl Cl
bamosiranum bamosiran
siRNA inhibitor of β2-adrenergic receptor production; RNA duplex of cytidylyl-(3'→5')-adenylyl-(3'→5')-uridylyl-(3'→5')uridylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')cytidylyl-(3'→5')-adenylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')uridylyl-(3'→5')-guanylyl-(3'→5')-adenylyl-(3'→5')-uridylyl-(3'→5')cytidylyl-(3'→5')-cytidylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')thymidylyl-(3'→5')-thymidine with thymidylyl-(5'→3')-thymidylyl(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-adenylyl-(5'→3')-adenylyl(5'→3')-cytidylyl-(5'→3')-adenylyl-(5'→3')-cytidylyl-(5'→3')-guanylyl(5'→3')-uridylyl-(5'→3')-adenylyl-(5'→3')-cytidylyl-(5'→3')-adenylyl(5'→3')-cytidylyl-(5'→3')-uridylyl-(5'→3')-adenylyl-(5'→3')-guanylyl(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-cytidine petit ARN interférant (siRNA) inhibiteur de la production du récepteur adrénergique β2; duplex ARN du brin cytidylyl-(3'→5')-adénylyl-(3'→5')-uridylyl(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-guanylyl(3'→5')-cytidylyl-(3'→5')-adénylyl-(3'→5')-uridylyl-(3'→5')-guanylyl(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-adénylyl-(3'→5')-uridylyl(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-adénylyl-(3'→5')-guanylyl(3'→5')-thymidylyl-(3'→5')-thymidine avec le brin anti-sens thymidylyl-(5'→3')-thymidylyl-(5'→3')-guanylyl-(5'→3')-uridylyl(5'→3')-adénylyl-(5'→3')-adénylyl-(5'→3')-cytidylyl-(5'→3')-adénylyl(5'→3')-cytidylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-adénylyl(5'→3')-cytidylyl-(5'→3')-adénylyl-(5'→3')-cytidylyl-(5'→3')-uridylyl(5'→3')-adénylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-uridylyl(5'→3')-cytidine ARN interferente pequeño (siRNA) inhibidor de la producción del receptor adrenérgico β2 ARN dúplex de la cadena citidilil-(3'→5')-adenilil-(3'→5')-uridilil(3'→5')-uridilil-(3'→5')-guanilil-(3'→5')-uridilil-(3'→5')-guanilil-(3'→5')citidilil-(3'→5')-adenilil-(3'→5')-uridilil-(3'→5')-guanilil-(3'→5')-uridilil(3'→5')-guanilil-(3'→5')-adenilil-(3'→5')-uridilil-(3'→5')-citidilil-(3'→5')citidilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-timidilil-(3'→5')timidina con la cadena antisentido timidilil-(5'→3')-timidilil-(5'→3')guanilil-(5'→3')-uridilil-(5'→3')-adenilil-(5'→3')-adenilil-(5'→3')-citidilil(5'→3')-adenilil-(5'→3')-citidilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')adenilil-(5'→3')-citidilil-(5'→3')-adenilil-(5'→3')-citidilil-(5'→3')-uridilil(5'→3')-adenilil-(5'→3')-guanilil-(5'→3')-guanilil-(5'→3')-uridilil(5'→3')-citidina C401H500N150O290P40
bamosiran
bamosirán
(3'-5')CAUUGUGCAUGUGAUCCAG-dT-dT (5'-3')dT-dT-GUAACACGUACACUAGGUC 303
Recommended INN: List 68
WHO Drug Information, Vol. 26, No. 3, 2012
brexpiprazolum brexpiprazole brexpiprazole brexpiprazol
7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin2(1H)-one 7-{4-[4-(1-benzothiophén-4-yl)pipérazin-1-yl]butoxy}quinoléin2(1H)-one 7-{4-[4-(1-benzotiofen-4-il)piperazin-1-il]butoxi}quinolin-2(1H)-ona C25H27N3O2S O H N O
N S N
buparlisibum buparlisib buparlisib buparlisib
5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin2-amine 5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluorométhyl)pyridin2-amine 5-[2,6-bis(morfolin-4-il)pirimidin-4-il]-4-(trifluorometil)piridin-2-amina C18H21F3N6O2 O N N N O F3C N N NH2
camicinalum camicinal camicinal camicinal
1-{4-[(3-fluorophenyl)amino]piperidin-1-yl}-2-(4-{[(3S)-3methylpiperazin-1-yl]methyl}phenyl)ethan-1-one 1-{4-[(3-fluorophényl)amino]pipéridin-1-yl}-2-(4-{[(3S)-3méthylpipérazin-1-yl]méthyl}phényl)éthan-1-one 1-{4-[(3-fluorofenil)amino]piperidin-1-il}-2-(4-{[(3S)-3-metilpiperazin1-il]metil}fenil)etan-1-ona C25H33FN4O N HN H CH3 O N N H F
304
WHO Drug Information, Vol. 26, No. 3, 2012
Recommended INN: List 68
caplacizumabum # caplacizumab
immunoglobulin VH-linker-VH fragment, anti-[Homo sapiens VWF (von Willebrand factor) A1 domain], humanized monoclonal antibody; VH-linker-VH chain (1-259) [humanized VH (Homo sapiens IGHV323*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (123) [8.8.21] (1-128)] trialanyl linker (129-131) -[humanized VH (Homo sapiens IGHV323*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (254) [8.8.21] (132-259) immunoglobuline fragment VH-linker-VH, anti-[Homo sapiens VWF (facteur de von Willebrand) domaine A1], anticorps monoclonal humanisé; chaîne VH-linker-VH (1-259) [VH humanisé (Homo sapiens IGHV323*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (123) [8.8.21] (1-128)] trialanyl linker (129-131) -[VH humanisé (Homo sapiens IGHV323*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (254) [8.8.21] (132-259) inmunoglobulina fragmento VH-conector-VH, anti-[VWF (factor de von Willebrand) de Homo sapiens dominio A1], anticuerpo monoclonal humanizado; cadena VH-conector-VH (1-259) [VH humanizado (Homo sapiens IGHV3-23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (123) [8.8.21] (1128)] -trialanil conector (129-131) -[VH humanizado (Homo sapiens IGHV3-23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (254) [8.8.21] (132-259) EVQLVESGGG ISRTGGSTYY VRAEDGRVRT LSCAASGRTF ISRDNAKRMV QGTQVTVSS LVQPGGSLRL PDSVEGRFTI LPSEYTFWGQ SYNPMGWFRQ YLQMNSLRAE SCAASGRTFS SRDNAKRMVY GTQVTVSSAA APGKGRELVA DTAVYYCAAA YNPMGWFRQA LQMNSLRAED AEVQLVESGG AISRTGGSTY GVRAEDGRVR PGKGRELVAA TAVYYCAAAG GLVQPGGSLR YPDSVEGRFT TLPSEYTFWG 50 100 150 200 250 259
caplacizumab
caplacizumab
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-chain 22-96 153-227
cerlapirdinum cerlapirdine cerlapirdine cerlapirdina
N,N-dimethyl-3-{[3-(naphthalene-1-sulfonyl)-1H-indazol5-yl]oxy}propan-1-amine N,N-diméthyl-3-{[3-(naphtaléne-1-sulfonyl)-1H-indazol5-yl]oxy}propan-1-amine N,N-dimetil-3-{[3-(naftaleno-1-sulfonil)-1H-indazol-5-il]oxi}propan1-amina C22H23N3O3S H N H3C N N CH3 O O S O
dexmecamylaminum dexmecamylamine dexmécamylamine dexmecamilamina
(1R,2S,4S)-N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine (1R,2S,4S)-N,2,3,3-tétraméthylbicyclo[2.2.1]heptan-2-amine (1R,2S,4S)-N,2,3,3-tetrametilbiciclo[2.2.1]heptan-2-amina
305
Recommended INN: List 68
WHO Drug Information, Vol. 26, No. 3, 2012
C11H21N H HN CH3 CH3 CH3 CH3
H
drisapersenum drisapersen
all-P-ambo-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-Pthiocytidylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methylP-thioadenylyl-(3'→5')-2'-O-methyl-P-thioguanylyl-(3'→5')-2'-Omethyl-P-thioguanylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thioguanylyl-(3'→5')2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thiouridylyl(3'→5')-2'-O-methyl-P-thioguanylyl-(3'→5')-2'-O-methyl-Pthioguanylyl-(3'→5')-2'-O-methyl-P-thiocytidylyl-(3'→5')-2'-O-methylP-thioadenylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-Omethyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-Omethyl-P-thiocytidylyl-(3'→5')-2'-O-methyluridine tout-P-ambo-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-méthyl-Pthiocytidylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthylP-thioadénylyl-(3'→5')-2'-O-méthyl-P-thioguanylyl-(3'→5')-2'-Ométhyl-P-thioguanylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thioguanylyl-(3'→5')2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl(3'→5')-2'-O-méthyl-P-thioguanylyl-(3'→5')-2'-O-méthyl-Pthioguanylyl-(3'→5')-2'-O-méthyl-P-thiocytidylyl-(3'→5')-2'-O-méthylP-thioadénylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-Ométhyl-P-thiouridylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-Ométhyl-P-thiocytidylyl-(3'→5')-2'-O-méthyluridine todo-P-ambo-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tiocitidilil(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tioadenilil(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metil-P-tioguanilil(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tioadenilil(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metil-P-tioadenilil(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metil-P-tiocitidilil-(3'→5')-2'-Ometil-P-tioadenilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-Ptiouridilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tiocitidilil(3'→5')-2'-O-metiluridina C211H275N76O119P19S19 (3'-5')(P-thio)(Um-Cm-Am-Am-Gm-Gm-Am-Am-Gm-Am-Um-Gm-Gm-Cm-Am-Um-Um-Um-Cm-Um)
drisapersen
drisapersén
faldaprevirum faldaprevir
(1R,2S)-1-{[(2S,4R)-4-[{8-bromo-7-methoxy2-[2-(2-methylpropanamido)-1,3-thiazol-4-yl]quinolin-4-yl}oxy]1-[(2S)-2-{[(cyclopentyloxy)carbonyl]amino}3,3-dimethylbutanoyl]pyrrolidine-2-carboxamido}2-ethenylcyclopropane-1-carboxylic acid
306
WHO Drug Information, Vol. 26, No. 3, 2012
Recommended INN: List 68
faldaprévir
acide (1R,2S)-1-{[(2S,4R)-4-[{8-bromo-7-méthoxy2-[2-(2-méthylpropanamido)-1,3-thiazol-4-yl]quinoléin-4-yl}oxy]1-[(2S)-2-{[(cyclopentyloxy)carbonyl]amino}3,3-diméthylbutanoyl]pyrrolidine-2-carboxamido}2-éthénylcyclopropane-1-carboxylique ácido (1R,2S)-1-{[(2S,4R)-4-[{8-bromo-7-methoxy2-[2-(2-metilpropanamido)-1,3-tiazol-4-il]quinolin-4-il}oxi]1-[(2S)-2-{[(ciclopentiloxi)carbonil]amino}3,3-dimetilbutanoil]pirrolidina-2-carboxamido}-2-etenilciclopropano1-carboxílico C40H49BrN6O9S Br H3CO N S NH N O H3 C O O N H CH3 CH3 H O N H O H H O H N CH3 CH3
faldaprevir
CO2H CH2
flanvotumabum # flanvotumab
immunoglobulin G1-kappa, anti-[Homo sapiens TYRP1 (tyrosinaserelated protein 1, 5,6-dihydroxyindole-2-carboxylic acid oxidase, DHICA oxidase, TRP1, melanoma antigen gp75)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV7-4-1*02 (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfide with kappa light chain (1'-215') [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ2*01) [6.3.10] (1'-108') IGKC*01 (109'-215')]; (228-228'':231-231'')-bisdisulfide dimer immunoglobuline G1-kappa, anti-[Homo sapiens TYRP1 (protéine 1 apparentée à la tyrosinase, oxydase de l'acide 5,6-dihydroxyindole2-carboxylique, DHICA-oxydase, TRP1, antigène gp75 du mélanome)], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-449) [Homo sapiens VH (IGHV7-4-1*02 (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfure avec la chaîne légère kappa (1'-215') [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ2*01) [6.3.10] (1'108') -IGKC*01 (109'-215')]; dimère (228-228'':231-231'')-bisdisulfure inmunoglobulina G1-kappa, anti-[TYRP1 de Homo sapiens (proteina 1 relacionada con la tirosinasa), oxidasa del ácido 5,6-dihidroxiindol2-carboxílico, DHICA-oxidasa, TRP1, antígeno gp75 de melanoma)], anticuerpo monoclonal de Homo sapiens; cadena pesada gamma1 (1-449) [Homo sapiens VH (IGHV7-4-1*02 (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfuro con la cadena ligera kappa (1'-215') [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ2*01) [6.3.10] (1'108') -IGKC*01 (109'-215')]; dímero (228-228'':231-231'')-bisdisulfuro
flanvotumab
flanvotumab
307
Recommended INN: List 68
WHO Drug Information, Vol. 26, No. 3, 2012
Heavy chain / Chaîne lourde / Cadena pesada QVQLVQSGSE LKKPGASVKI SCKASGYTFT INTNTGNPTY AQGFTGRFVF SMDTSVSTAY SSSWYLDYWG QGTLVTVSSA STKGPSVFPL YFPEPVTVSW NSGALTSGVH TFPAVLQSSG ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP DTLMISRTPE VTCVVVDVSH EDPEVKFNWY TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL YTLPPSREEM TKNQVSLTCL VKGFYPSDIA DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM Light chain / Chaîne légère / Cadena ligera EIVLTQSPAT LSLSPGERAT LSCRASQSVS ASNRATGIPA RFSGSGSGTD FTLTISSLEP QGTKLEIKRT VAAPSVFIFP PSDEQLKSGT VDNALQSGNS QESVTEQDSK DSTYSLSSTL GLSSPVTKSF NRGEC
SYAMNWVRQA LQISSLKAED APSSKSTSGG LYSLSSVVTV CPAPELLGGP VDGVEVHNAK PAPIEKTISK VEWESNGQPE HEALHNHYTQ SYLAWYQQKP EDFAVYYCQQ ASVVCLLNNF TLSKADYEKH
PGQGLESMGW TAIYYCAPRY TAALGCLVKD PSSSLGTQTY SVFLFPPKPK TKPREEQYNS AKGQPREPQV NNYKTTPPVL KSLSLSPGK
50 100 150 200 250 300 350 400 449
GQAPRLLIYD 50 RSNWLMYTFG 100 YPREAKVQWK 150 KVYACEVTHQ 200 215
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 146-202 263-323 369-427 22''-96'' 146''-202'' 263''-323'' 369''-427'' Intra-L 23'-88' 135'-195' 23'''-88''' 135'''-195''' Inter-H-L 222-215' 222''-215''' Inter-H-H 228-228'' 231-231'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 299, 299''
follitropinum gamma # follitropin gamma
heterodimer of human glycoprotein hormones alpha chain and follitropin subunit beta (FSH-beta), follicle stimulating hormone, glycoform gamma hétérodimère constitué de la chaîne alpha des hormones glycoprotéiques et de la sous-unité bêta de la follitropine (FSH-bêta) humaines, hormone folliculostimulante, forme glycosylée gamma heterodímero formado por la cadena alfa de las hormonas glicoprotéicas y la subunidad beta de la folitropina (FSH-beta) humanas, hormona estimulante del folículo, forma glicosilada gamma C975H1493N267O305S26 (peptide) Alpha subunit / Sous-unité alpha / Subunidad alfa APDVQDCPEC TLQENPFFSQ PGAPILQCMG CCFSRAYPTP LRSKKTMLVQ KNVTSESTCC VAKSYNRVTV MGGFKVENHT ACHCSTCYYH KS 50 92
follitropine gamma
folitropina gamma
Beta subunit / Sous-unité bêta / Subunidad beta NSCELTNITI AIEKEECRFC ISINTTWCAG YCYTRDLVYK DPARPKIQKT 50' CTFKELVYET VRVPGCAHHA DSLYTYPVAT QCHCGKCDSD STDCTVRGLG 100' 111' PSYCSFGEMK E Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 7-31 10-60 28-82 32-84 59-87 3'-51' 17'-66' 20'-104' 28'-82' 32'-84' 87'-94' Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N) Asn-7' Asn-24' Asn-52 Asn-78 R66R33--Gal4--Gl-N2R44R33--Gal4--Gl-N2-Man6-Man3R -Man--Gl-N -Gl-NN
R = -Fuc or H, R3 = -Sia or H, R4 and R6 = R33--Gal4--Gl-N or H
308
WHO Drug Information, Vol. 26, No. 3, 2012
Recommended INN: List 68
gemcitabini elaidas gemcitabine elaidate élaïdate de gemcitabine elaidato de gemcitabina
2'-deoxy-2',2'-difluorocytidine 5'-(9E)-octadec-9-enoate 5'-(9E)-octadéc-9-énoate de 2'-déoxy-2',2'-difluorocytidine 5'-(9E)-octadec-9-enoato de 2'-desoxi-2',2'-difluorocitidina C27H43F2N3O5 NH2 N O O O O N
F OH
CH3
F
glyceroli phenylbutyras glycerol phenylbutyrate phénylbutyrate de glycérol fenilbutirato de glicerol
propane-1,2,3-triyl tris(4-phenylbutanoate) tris(4-phénylbutanoate) de propane-1,2,3-triyle tris(4-fenilbutanoato) de propano-1,2,3-triilo C33H38O6 O O O O O O
idursulfasum beta # idursulfase beta idursulfase bêta idursulfasa beta
iduronate 2-sulfatase (α-L-iduronate sulfate sulfatase), human proenzyme produced in CHO cells (glycoform beta) iduronate 2-sulfatase (α-L-iduronate sulfate sulfatase), proenzyme humaine produite par des cellules CHO (glycoforme bêta) iduronato 2-sulfatasa (α-L-iduronato sulfato sulfatasa), proenzima humana producida por células CHO (forma glicosilada beta)
309
Recommended INN: List 68
WHO Drug Information, Vol. 26, No. 3, 2012
C2689H4051N699O793S13 SETQANSTTD NAFAQQAVCA NGYVTMSVGK GELHANLLCP HKPHIPFRYP VQALNISVPY STIIAFTSDH KLFPYLDPFD SFHVELCREG NSDKPSLKDI DSDPLQDHNM ALNVLLIIVD PSRVSFLTGR VFHPGISSNH VDVLDVPEGT KEFQKLYPLE GPIPVDFQRK GWALGEHGEW SASQLMEPGR KNLLKHFRFR KIMGYSIRTI YNDSQGGDLF DLRPSLGCYG RPDTTRLYDF TDDSPYSWSF LPDKQSTEQA NITLAPDPEV IRQSYFASVS AKYSNFDVAT QSMDLVELVS DLEEDPYLPG DYRYTVWVGF QLLMP DKLVRSPNID NSYWRVHAGN PPYHPSSEKY IQLLEKMKTS PDGLPPVAYN YLDTQVGRLL HVPLIFYVPG LFPTLAGLAG NPRELIAYSQ NPDEFLANFS QLASHSLLFQ FSTIPQYFKE ENTKTCRGPD ASPFFLAVGY PWMDIRQRED SALDDLQLAN RTASLPEAGE LQVPPRCPVP YPRPSDIPQW DIHAGELYFV 50 100 150 200 250 300 350 400 450 500 525
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 146-159 397-407 Modified residue / Résidu modifié / Residuo modificado C 59 3-oxoAla H O NH2 CO2H
Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N) Asn-6 Asn-90 Asn-119 Asn-221 Asn-255 Asn-300 Asn-488 Asn-512
inclacumabum # inclacumab
immunoglobulin G4-kappa, anti-[Homo sapiens SELP (selectin P, CD62)], Homo sapiens monoclonal antibody; gamma4 heavy chain (1-451) [Homo sapiens VH (IGHV3-13*01 (94.80%) -(IGHD)-IGHJ5*02) [8.7.18] (1-124) -IGHG4*01 hinge S10>P (232), CH2 L1.2>E (239) (125-451)], (138-214')-disulfide with kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*02) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (230230'':233-233'')-bisdisulfide dimer immunoglobuline G4-kappa, anti-[Homo sapiens SELP (sélectine P, CD62)], Homo sapiens anticorps monoclonal; chaîne lourde gamma4 (1-451) [Homo sapiens VH (IGHV3-13*01 (94.80%) -(IGHD)-IGHJ5*02) [8.7.18] (1-124) -IGHG4*01 charnière S10>P (232), CH2 L1.2>E (239) (125-451)], (138-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*02) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (230-230'':233-233'')-bisdisulfure inmunoglobulina G4-kappa, anti-[SELP de Homo sapiens (selectina P, CD62)], anticuerpo monoclonal de Homo sapiens ; cadena pesada gamma4 (1-451) [Homo sapiens VH (IGHV3-13*01 (94.80%) -(IGHD)-IGHJ5*02) [8.7.18] (1-124) -IGHG4*01 bisagra S10>P (232), CH2 L1.2>E (239) (125-451)], (138-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV311*01 (100.00%) -IGKJ4*02) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (230-230'':233-233'')-bisdisulfuro
inclacumab
inclacumab
310
WHO Drug Information, Vol. 26, No. 3, 2012
Recommended INN: List 68
Heavy chain / Chaîne lourde / Cadena pesada EVQLVESGGG LVRPGGSLRL SCAASGFTFS ITAAGDIYYP GSVKGRFTIS RENAKNSLYL SGSGSYYNDW FDPWGQGTLV TVSSASTKGP CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV GTKTYTCNVD HKPSNTKVDK RVESKYGPPC PKDTLMISRT PEVTCVVVDV SQEDPEVQFN NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK QVYTLPPSQE EMTKNQVSLT CLVKGFYPSD VLDSDGSFFL YSRLTVDKSR WQEGNVFSCS K Light chain / Chaîne légère / Cadena ligera EIVLTQSPAT LSLSPGERAT LSCRASQSVS ASNRATGIPA RFSGSGSGTD FTLTISSLEP GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSSPVTKSFN RGEC
NYDMHWVRQA QMNSLRAGDT SVFPLAPCSR LQSSGLYSLS PPCPAPEFEG WYVDGVEVHN GLPSSIEKTI IAVEWESNGQ VMHEALHNHY
TGKGLEWVSA AVYYCARGRY STSESTAALG SVVTVPSSSL GPSVFLFPPK AKTKPREEQF SKAKGQPREP PENNYKTTPP TQKSLSLSLG
50 100 150 200 250 300 350 400 450 451
SYLAWYQQKP EDFAVYYCQQ SVVCLLNNFY LSKADYEKHK
GQAPRLLIYD 50 RSNWPLTFGG 100 PREAKVQWKV 150 VYACEVTHQG 200 214
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-95 151-207 265-325 371-429 22''-95'' 151''-207'' 265''-325'' 371''-429'' Intra-L 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L 138-214' 138''-214''' Inter-H-H 230-230'' 233-233'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 301, 301''
lucerastatum lucerastat lucérastat lucerastat
(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol (2R,3S,4R,5S)-1-butyl-2-(hydroxyméthyl)pipéridine-3,4,5-triol (2R,3S,4R,5S)-1-butil-2-(hidroximetil)piperidina-3,4,5-triol C10H21NO4 OH HO H HO H H N H OH CH3
naltalimidum naltalimide naltalimide naltalimida
2-[17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan6β-yl]isoindole-1,3-dione 2-[-17-(cyclopropylméthyl)-4,5α-époxy-3,14-dihydroxymorphinan6β-yl]-2H-isoindole-1,3-dione 2-[17-(ciclopropilmetil)-4,5α-epoxi-3,14-dihidroximorfinan6β-il]isoindol-1,3-diona
311
Recommended INN: List 68
WHO Drug Information, Vol. 26, No. 3, 2012
C28H28N2O5 H HO O HO O H H O N N
netazepidum netazepide
1-[(3R)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-(pyridin-2-yl)2,3-dihydro-1H-1,4-benzodiazepin-3-yl]3-[3-(methylamino)phenyl]urea 1-[(3R)-1-(3,3-diméthyl-2-oxobutyl)-2-oxo-5-(pyridin-2-yl)2,3-dihydro-1H-1,4-benzodiazépin-3-yl]3-[3-(méthylamino)phényl]urée 1-[(3R)-1-(3,3-dimetil-2-oxobutil)-2-oxo-5-(piridin-2-il)-2,3-dihidro1H-1,4-benzodiazepin-3-il]-3-[3-(metilamino)fenil]urea C28H30N6O3 H3C O CH3 CH3 HN N N N O H N H O N H
nétazépide
netazepida
CH3
niraparibum niraparib niraparib niraparib
2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide 2-{4-[(3S)-pipéridin-3-yl]phényl}-2H-indazole-7-carboxamide 2-{4-[(3S)-piperidin-3-il]fenil}-2H-indazol-7-carboxamida C19H20N4O H N N H N O NH2
312
WHO Drug Information, Vol. 26, No. 3, 2012
Recommended INN: List 68
ondelopranum ondelopran ondélopran ondeloprán
6-[2-fluoro-4-({[2-(oxan-4-yl)ethyl]amino}methyl)phenoxy]pyridine3-carboxamide 6-[2-fluoro-4-({[2-(oxan-4-yl)éthyl]amino}méthyl)phénoxy]pyridine3-carboxamide 6-[2-fluoro-4-({[2-(oxan-4-il)etil]amino}metil)fenoxi]piridina3-carboxamida C20H24FN3O3 O N H O F N O NH2
patiromerum calcium patiromer calcium patiromère calcique patirómero cálcico
cross-linked polymer of calcium 2-fluoroprop-2-enoate with diethenylbenzene and octa-1,7-diene polymère réticulé de 2-fluoroprop-2-énoate de calcium avec du diéthénylbenzène et de l'octa-1,7-diène polímero reticulado de 2-fluoroprop-2-enoato de calcio con dietenilbenceno y octa-1,7-dieno [[(C3H2FO2)2 Ca]9 [C8H14] [C10H10]]n H2C F x/2 Ca 2+
CO2 x
CH2 H2C H2C CH2 z y
patritumabum # patritumab
immunoglobulin G1-kappa, anti-[Homo sapiens ERBB3 (receptor tyrosine-protein kinase erbB-3, HER3)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-447) [Homo sapiens VH (IGHV4-34*01 (99.00%) -(IGHD)-IGHJ2*01) [8.7.11] (1-117) -IGHG1*03 (118-447)], (220-220')-disulfide with kappa light chain (1'-220') [Homo sapiens V-KAPPA (IGKV4-1*01 (95.00%) -IGKJ1*01) [12.3.9] (1'-113') IGKC*01 (114'-220')]; (226-226'':229-229'')-bisdisulfide dimer immunoglobuline G1-kappa, anti-[Homo sapiens ERBB3 (récepteur tyrosine-protéine kinase erbB3, HER3)], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-447) [Homo sapiens VH (IGHV4-34*01 (99.00%) -(IGHD)-IGHJ2*01) [8.7.11] (1-117) -IGHG1*03 (118-447)], (220-220')-disulfure avec la chaîne légère kappa (1'-220') [Homo sapiens V-KAPPA (IGKV4-1*01 (95.00%) -IGKJ1*01) [12.3.9] (1'113') -IGKC*01 (114'-220')]; dimère (226-226'':229-229'')-bisdisulfure
patritumab
313
Recommended INN: List 68
WHO Drug Information, Vol. 26, No. 3, 2012
patritumab
inmunoglobulina G1-kappa, anti-[Homo sapiens ERBB3 (receptor de tirosina-proteina kinasa erbB3, HER3)], anticuerpo monoclonal de Homo sapiens; cadena pesada gamma1 (1-447) [Homo sapiens VH (IGHV4-34*01 (99.00%) -(IGHD)-IGHJ2*01) [8.7.11] (1-117) -IGHG1*03 (118-447)], (220-220')-disulfuro con la cadena ligera kappa (1'-220') [Homo sapiens V-KAPPA (IGKV4-1*01 (95.00%) -IGKJ1*01) [12.3.9] (1'113') -IGKC*01 (114'-220')]; dímero (226-226'':229-229'')-bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada QVQLQQWGAG LLKPSETLSL TCAVYGGSFS INHSGSTNYN PSLKSRVTIS VETSKNQFSL TWYFDLWGRG TLVTVSSAST KGPSVFPLAP PEPVTVSWNS GALTSGVHTF PAVLQSSGLY NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP LMISRTPEVT CVVVDVSHED PEVKFNWYVD RVVSVLTVLH QDWLNGKEYK CKVSNKALPA LPPSREEMTK NQVSLTCLVK GFYPSDIAVE DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE Light chain / Chaîne légère / Cadena ligera DIEMTQSPDS LAVSLGERAT INCRSSQSVL KLLIYWASTR ESGVPDRFSG SGSGTDFTLT PRTFGQGTKV EIKRTVAAPS VFIFPPSDEQ KVQWKVDNAL QSGNSQESVT EQDSKDSTYS EVTHQGLSSP VTKSFNRGEC GYYWSWIRQP KLSSVTAADT SSKSTSGGTA SLSSVVTVPS APELLGGPSV GVEVHNAKTK PIEKTISKAK WESNGQPENN ALHNHYTQKS YSSSNRNYLA ISSLQAEDVA LKSGTASVVC LSSTLTLSKA PGKGLEWIGE AVYYCARDKW ALGCLVKDYF SSLGTQTYIC FLFPPKPKDT PREEQYNSTY GQPREPQVYT YKTTPPVLDS LSLSPGK 50 100 150 200 250 300 350 400 447
WYQQNPGQPP 50 VYYCQQYYST 100 LLNNFYPREA 150 DYEKHKVYAC 200 220
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-95 144-200 261-321 367-425 22''-95'' 144''-200'' 261''-321'' 367''-425'' Intra-L 23'-94' 140'-200' 23'''-94''' 140'''-200''' Inter-H-L 220-220' 220''-220''' Inter-H-H 226-226'' 229-229'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 297, 297''
plazomicinum plazomicin
(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-{[(2S,3R)-3-amino6-{[(2-hydroxyethyl)amino]methyl}-3,4-dihydro-2H-pyran-2-yl]oxy}2-{[3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl]oxy}3-hydroxycyclohexyl]-2-hydroxybutanamide (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-{[(2S,3R)-3-amino6-{[(2-hydroxyéthyl)amino]méthyl}-3,4-dihydro-2H-pyran-2-yl]oxy}2-{[3-déoxy-4-C-méthyl-3-(méthylamino)-β-L-arabinopyranosyl]oxy}3-hydroxycyclohexyl]-2-hydroxybutanamide (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-{[(2S,3R)-3-amino6-{[(2-hidroxietil)amino]metil}-3,4-dihidro-2H-piran-2-il]oxi}2-{[3-desoxi-4-C-metil-3-(metilamino)-β-L-arabinopiranosil]oxi}3-hidroxiciclohexil]-2-hidroxibutanamida C25H48N6O10 HO HO HN H3C OH O HO NH2 HN O CH3 O HN H OH O NH2
plazomicine
plazomicina
NH2
O
pradigastatum pradigastat
{(1r,4r)-4-[4-(5-{[6-(trifluoromethyl)pyridin-3-yl]amino}pyridin-2-yl) phenyl]cyclohexyl}acetic acid
314
WHO Drug Information, Vol. 26, No. 3, 2012
Recommended INN: List 68
pradigastat pradigastat
acide {trans-4-[4-(5-{[6-(trifluorométhyl)pyridin-3-yl]amino}pyridin2-yl)phényl]cyclohexyl}acétique ácido {(1r,4r)-4-[4-(5-{[6-(trifluorometil)piridin-3-il]amino}piridin-2-il) fenil]ciclohexil}acético C25H24F3N3O2 CO2H
F 3C
N N H
N
pritelivirum pritelivir pritélivir pritelivir
N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin2-yl)phenyl]acetamide N-méthyl-N-(4-méthyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin2-yl)phényl]acétamide N-metil-N-(4-metil-5-sulfamoil-1,3-tiazol-2-il)-2-[4-(pyridin2-il)fenil]acetamida C18H18N4O3S2 N O N CH3 N S S O CH3 NH2 O
quilizumabum # quilizumab
immunoglobulin G1-kappa, anti-[Homo sapiens IGHE connecting region (CO) M1 prime (in alternatively spliced heavy chain of membrane IgE on B cells)], humanized monoclonal antibody; gamma1 heavy chain (1-447) [humanized VH (Homo sapiens IGHV3-48*01 (85.70%) -(IGHD)-IGHJ3*01 M123>L (112) [8.8.10] (1117) -Homo sapiens IGHG1*03 CH1 R120>K (214) (118-447)], (220219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; (226-226":229-229")bisdisulfide dimer immunoglobuline G1-kappa, anti-[Homo sapiens IGHE région de connexion (CO) M1 prime (dans la chaîne lourde des IgE membranaires à la surface des lymphocytes B, épissée de manière alternative)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-447) [VH humanisé (Homo sapiens IGHV3-48*01 (85.70%) -(IGHD)-IGHJ3*01 M123>L (112) [8.8.10] (1117) -Homo sapiens IGHG1*03 CH1 R120>K (214) (118-447)], (220219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (226226":229-229")-bisdisulfure 315
quilizumab
Recommended INN: List 68
WHO Drug Information, Vol. 26, No. 3, 2012
quilizumab
inmunoglobulina G1-kappa, anti-[Homo sapiens IGHE región de conexión (CO) M1 prime (en la cadena pesada de las IgE de membrana de la superficie de los linfocitos B, ensamblada de modo alternativo)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-447) [VH humanizado (Homo sapiens IGHV3-48*01 (85.70%) -(IGHD)-IGHJ3*01 M123>L (112) [8.8.10] (1117) -Homo sapiens IGHG1*03 CH1 R120>K (214) (118-447)], (220219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dímero (226226":229-229")-bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada EVQLVESGGG LVQPGGSLRL SCAASGFTFS ISDLAYTIYY ADTVTGRFTI SRDNSKNTLY WDAMDYWGQG TLVTVSSAST KGPSVFPLAP PEPVTVSWNS GALTSGVHTF PAVLQSSGLY NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP LMISRTPEVT CVVVDVSHED PEVKFNWYVD RVVSVLTVLH QDWLNGKEYK CKVSNKALPA LPPSREEMTK NQVSLTCLVK GFYPSDIAVE DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS LSASVGDRVT ITCRSSQSLV LLIYKVSNRF SGVPSRFSGS GSGTDFTLTI WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL VQWKVDNALQ SGNSQESVTE QDSKDSTYSL VTHQGLSSPV TKSFNRGEC
DYGIAWVRQA LQMNSLRAED SSKSTSGGTA SLSSVVTVPS APELLGGPSV GVEVHNAKTK PIEKTISKAK WESNGQPENN ALHNHYTQKS HNNANTYLHW SSLQPEDFAT KSGTASVVCL SSTLTLSKAD
PGKGLEWVAF TAVYYCARDN ALGCLVKDYF SSLGTQTYIC FLFPPKPKDT PREEQYNSTY GQPREPQVYT YKTTPPVLDS LSLSPGK
50 100 150 200 250 300 350 400 447
YQQKPGKAPK 50 YYCSQNTLVP 100 LNNFYPREAK 150 YEKHKVYACE 200 219
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 144-200 261-321 367-425 22''-96'' 144''-200'' 261''-321'' 367''-425'' Intra-L 23'-93' 139'-199' 23'''-93''' 139'''-199''' Inter-H-L 220-219' 220''-219''' Inter-H-H 226-226'' 229-229'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 297, 297'' (non-fucosylated oligosaccharides)
radavirsenum radavirsen
all-P-ambo-P,2',3'-trideoxy-P-(dimethylamino)-5'-O-{P-[4-({2-[2-(2hydroxyethoxy)ethoxy]ethoxy}carbonyl)piperazin-1-yl]-N,Ndimethylphosphonamidoyl}-(2'a→5')-P,2',3'-trideoxy-P(dimethylamino)-2',3'-imino-2',3'-secocytidylyl-(2'a→5')-P,2',3'trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoguanyly-(2'a→5')P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoguanyly(2'a→5')-P,3'-dideoxy-P-(piperazin-1-yl)-2',3'-imino-2',3'secothymidylyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)-2',3'-imino2',3'-secothymidylyl-(2'a→5')-P,2',3'-trideoxy-P-(dimethylamino)-2',3'imino-2',3'-secoadenylyl-(2'a→5')-P,2',3'-trideoxy-P-(dimethylamino)2',3'-imino-2',3'-secoguanyly-(2'a→5')-P,2',3'-trideoxy-P(dimethylamino)-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-P,2',3'trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoadenylyl-(2'a→5')P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoguanyly(2'a→5')-P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'secoadenylyl-(2'a→5')-P,2',3'-trideoxy-P-(piperazin-1-yl)-2',3'-imino2',3'-secocytidylyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)-2',3'imino-2',3'-secothymidylyl-(2'a→5')-P,2',3'-trideoxy-P(dimethylamino)-2',3'-imino-2',3'-secocytidylyl-(2'a→5')-P,2',3'trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoadenylyl-(2'a→5')P,3'-dideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secothymidylyl(2'a→5')-P,2',3'-trideoxy-P-(piperazin-1-yl)-2',3'-imino-2',3'secocytidylyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)-2',3'-imino2',3'-secothymidylyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)-2',3'imino-2',3'-secothymidylyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)2',3'-imino-2',3'-secothymidine
316
WHO Drug Information, Vol. 26, No. 3, 2012
Recommended INN: List 68
radavirsen
tout-P-ambo-P,2',3'-tridéoxy-P-(diméthylamino)-5'-O-{P-[4-({2-[2-(2hydroxyéthoxy)éthoxy]éthoxy}carbonyl)pipérazin-1-yl]-N,Ndiméthylphosphonamidoyl}-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')P,2',3'-tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'-sécoguanylyl(2'a→5')-P,2',3'-tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'sécoguanylyl-(2'a→5')-P,3'-didéoxy-2',3'-imino-P-(pipérazin-1-yl)2',3'-sécothymidylyl-(2'a→5')-P,3'-didéoxy-P-(diméthylamino)-2',3'imino-2',3'-sécothymidylyl-(2'a→5')-P,2',3'-tridéoxy-P(diméthylamino)-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-P,2',3'tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'-sécoguanylyl-(2'a→5')P,2',3'-tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'-sécoadénylyl(2'a→5')-P,2',3'-tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'sécoadenylyl-(2'a→5')-P,2',3'-tridéoxy-P-(diméthylamino)-2',3'-imino2',3'-sécoguanylyl-(2'a→5')-P,2',3'-tridéoxy-P-(diméthylamino)-2',3'imino-2',3'-sécoadénylyl-(2'a→5')-P,2',3'-tridéoxy-2',3'-imino-P(pipérazin-1-yl)-2',3'-sécocytidylyl-(2'a→5')-P,3'-didéoxy-P(diméthylamino)-2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-P,2',3'tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')P,2',3'-tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'-sécoadénylyl(2'a→5')-P,3'-didéoxy-P-(dimethylamino)-2',3'-imino-2',3'sécothymidylyl-(2'a→5')-P,2',3'-tridéoxy-2',3'-imino-P-(pipérazin-1yl)-2',3'-sécocytidylyl-(2'a→5')-P,3'-didéoxy-P-(diméthylamino)-2',3'imino-2',3'-sécothymidylyl-(2'a→5')-P,3'-didéoxy-P-(diméthylamino)2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-3'-déoxy-2',3'-imino-2',3'sécothymidine
radavirsén
todo-P-ambo-P,2',3'-tridesoxi-P-(dimetilamino)-5'-O-{P-[4-({2-[2-(2hidroxietoxi)etoxi]etoxi}carbonil)piperazin-1-il]-N,Ndimetilfosfonamidoil}-(2'a→5')-P,2',3'-tridesoxi-P-(dimetilamino)-2',3'imino-2',3'-secocitidilil-(2'a→5')-P,2',3'-tridesoxi-P-(dimetilamino)2',3'-imino-2',3'-secoguanilil-(2'a→5')-P,2',3'-tridesoxi-P(dimetilamino)-2',3'-imino-2',3'-secoguanilil-(2'a→5')-P,3'-didesoxi-P(piperazin-1-il)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,3'-didesoxi-P(dimetilamino)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,2',3'-tridesoxiP-(dimetilamino)-2',3'-imino-2',3'-secoadenilil-(2'a→5')-P,2',3'tridesoxi-P-(dimetilamino)-2',3'-imino-2',3'-secoguanilil-(2'a→5')P,2',3'-tridesoxi-P-(dimetilamino)-2',3'-imino-2',3'-secoadenilil(2'a→5')-P,2',3'-tridesoxi-P-(dimetilamino)-2',3'-imino-2',3'secoadenilil-(2'a→5')-P,2',3'-tridesoxi-P-(dimetilamino)-2',3'-imino2',3'-secoguanilil-(2'a→5')-P,2',3'-tridesoxi-P-(dimetilamino)-2',3'imino-2',3'-secoadenilil-(2'a→5')-P,2',3'-tridesoxi-P-(piperazin-1-il)2',3'-imino-2',3'-secocitidilil-(2'a→5')-P,3'-didesoxi-P-(dimetilamino)2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,2',3'-tridesoxi-P(dimetilamino)-2',3'-imino-2',3'-secocitidilil-(2'a→5')-P,2',3'-tridesoxiP-(dimetilamino)-2',3'-imino-2',3'-secoadenilil-(2'a→5')-P,3'-didesoxiP-(dimetilamino)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,2',3'tridesoxi-P-(piperazin-1-il)-2',3'-imino-2',3'-secocitidilil-(2'a→5')-P,3'didesoxi-P-(dimetilamino)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,3'didesoxi-P-(dimetilamino)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,3'didesoxi-P-(dimetilamino)-2',3'-imino-2',3'-secotimidina
317
Recommended INN: List 68
WHO Drug Information, Vol. 26, No. 3, 2012
C253H398N116O87P20 O O HO 3
B(n) N N H 3C P O 5'
B(20) O
O 1' 2'a
N
P
O 19
NH
n = 1 - 19
N O CH3
R(n) O
B(1-20) : C-G-G-T-T-A-G-A-A-G-A-C-T-C-A-T-C-T-T-T R(1-3) = R(5-11) = R(13-16) = R(18) = R(19) = -N(CH3)2 R(4) = R(12) = R(17) = HN N
rafigrelidum rafigrelide rafigrélide rafigrelida
6,7-dichloro-3,3-dimethyl-5,10-dihydroimidazo[2,1-b]quinazolin2(3H)-one 6,7-dichloro-3,3-diméthyl-1,5-dihydroimidazo[2,1-b]quinazolin2(3H)-one 6,7-dicloro-3,3-dimetil-5,10-dihidroimidazo[2,1-b]quinazolin2(3H)-ona C12H11Cl2N3O N Cl Cl N H3C H N O CH3
refametinibum refametinib réfamétinib refametinib
N-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide N-{3,4-difluoro-2-[(2-fluoro-4-iodophényl)amino]-6-méthoxyphényl}1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide N-{3,4-difluoro-2-[(2-fluoro-4-iodofenil)amino]-6-metoxifenil}1-[(2S)-2,3-dihidroxipropil]ciclopropano-1-sulfonamida C19H20F3IN2O5S CH3 F F NH I F O O O S N H
OH H OH
318
WHO Drug Information, Vol. 26, No. 3, 2012
Recommended INN: List 68
rigosertibum rigosertib rigosertib rigosertib
N-[2-methoxy-5-({[(1E)-2-(2,4,6trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine N-[2-méthoxy-5-({[(1E)-2-(2,4,6triméthoxyphényl)éthényl]sulfonyl}méthyl)phényl]glycine N-[2-metoxi-5-({[(1E)-2-(2,4,6trimetoxifenil)etenil]sulfonil}metil)fenil]glicina C21H25NO8S H3CO OCH3 S OCH3 O O H N OCH3 CO2H
riodipinum riodipine riodipine riodipino
dimethyl 4-[2-(difluoromethoxy)phenyl]-2,6-dimethyl1,4-dihydropyridine-3,5-dicarboxylate 4-[2-(difluorométhoxy)phényl]-2,6-diméthyl-1,4-dihydropyridine3,5-dicarboxylate de diméthyle 4-[2-(difluorometoxi)fenil]-2,6-dimetil-1,4-dihidropiridina3,5-dicarboxilato de dimetilo C18H19F2NO5 H3C H3C O O O O F H N CH3 O CH3 F
romosozumabum # romosozumab
immunoglobulin G2-kappa, anti-[Homo sapiens SOST (sclerostin)], humanized monoclonal antibody; gamma2 heavy chain (1-449) [humanized VH (Homo sapiens IGHV1-2*02 (87.80%) -(IGHD)-IGHJ2*01 R120>Q (115), L123>T (118) [8.8.16] (1-123) -Homo sapiens IGHG2*01 (124-449)], (137214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-33*01 (89.50%) -IGKJ4*02) [6.3.9] (1'-107') Homo sapiens IGKC*01 (108'-214')]; (225-225":226-226":229229":232-232")-tetrakisdisulfide dimer immunoglobuline G2-kappa, anti-[Homo sapiens SOST (sclérostine)], anticorps monoclonal humanisé; chaîne lourde gamma2 (1-449) [VH humanisé (Homo sapiens IGHV1-2*02 (87.80%) -(IGHD)-IGHJ2*01 R120>Q (115), L123>T (118) [8.8.16] (1-123) -Homo sapiens IGHG2*01 (124-449)], (137214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-33*01 (89.50%) -IGKJ4*02) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (225225":226-226":229-229":232-232")-tétrakisdisulfure
romosozumab
319
Recommended INN: List 68
WHO Drug Information, Vol. 26, No. 3, 2012
romosozumab
inmunoglobulina G2-kappa, anti-[SOST (esclerostina) de Homo sapiens], anticuerpo monoclonal humanizado; cadena pesada gamma2 (1-449) [VH humanizado (Homo sapiens IGHV1-2*02 (87.80%) -(IGHD)-IGHJ2*01 R120>Q (115), L123>T (118) [8.8.16] (1-123) -Homo sapiens IGHG2*01 (124-449)], (137214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (Homo sapiens IGKV1-33*01 (89.50%) -IGKJ4*02) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (225225":226-226":229-229":232-232")-tetrakisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada EVQLVQSGAE VKKPGASVKV SCKASGYTFT INPNSGGAGY NQKFKGRVTM TTDTSTSTAY YDDIYDDWYF DVWGQGTTVT VSSASTKGPS LVKDYFPEPV TVSWNSGALT SGVHTFPAVL TQTYTCNVDH KPSNTKVDKT VERKCCVECP DTLMISRTPE VTCVVVDVSH EDPEVQFNWY TFRVVSVLTV VHQDWLNGKE YKCKVSNKGL YTLPPSREEM TKNQVSLTCL VKGFYPSDIA DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS LSASVGDRVT ITCRASQDIS TSRLLSGVPS RFSGSGSGTD FTLTISSLQP GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSSPVTKSFN RGEC DYNMHWVRQA MELRSLRSDD VFPLAPCSRS QSSGLYSLSS PCPAPPVAGP VDGVEVHNAK PAPIEKTISK VEWESNGQPE HEALHNHYTQ NYLNWYQQKP EDFATYYCQQ SVVCLLNNFY LSKADYEKHK PGQGLEWMGE TAVYYCARLG TSESTAALGC VVTVPSSNFG SVFLFPPKPK TKPREEQFNS TKGQPREPQV NNYKTTPPML KSLSLSPGK 50 100 150 200 250 300 350 400 449
GKAPKLLIYY 50 GDTLPYTFGG 100 PREAKVQWKV 150 VYACEVTHQG 200 214
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 150-206 263-323 369-427 22''-96'' 150''-206'' 263''-323'' 369''-427'' Intra-L 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L 137-214' 137''-214''' Inter-H-H 225-225'' 226-226'' 229-229'' 232-232'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 299, 299''
samidorphanum samidorphan samidorphan samidorfano
17-(cyclopropylmethyl)-4,14-dihydroxy-6-oxomorphinan3-carboxamide 17-(cyclopropylméthyl)-4,14-dihydroxy-6-oxomorphinane3-carboxamide 17-(ciclopropilmetil)-4,14-dihidroxi-6-oxomorfinan-3-carboxamida C21H26N2O4 H HO N
H2N O
OH
O
sapitinibum sapitinib sapitinib
2-[4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin6-yl}oxy)piperidin-1-yl]-N-methylacetamide 2-[4-({4-[(3-chloro-2-fluorophényl)amino]-7-méthoxyquinazolin6-yl}oxy)pipéridin-1-yl]-N-méthylacétamide
320
WHO Drug Information, Vol. 26, No. 3, 2012
Recommended INN: List 68
sapitinib
2-[4-({4-[(3-cloro-2-fluorofenil)amino]-7-metoxiquinazolin6-il}oxi)piperidin-1-il]-N-metilacetamida C23H25ClFN5O3 H3 C H N O CH3 N O O HN N N F Cl
sarilumabum # sarilumab
immunoglobulin G1-kappa, anti-[Homo sapiens IL6R (interleukin 6 receptor, IL-6R, CD126)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-446) [Homo sapiens VH (IGHV3-9*01 (94.90%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*01 (117-446)], (219-214')-disulfide with kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (96.80%) -IGKJ2*01) [6.3.9] (1'-107') IGKC*01 (108'-214')]; (225-225'':228-228'')-bisdisulfide dimer immunoglobuline G1-kappa, anti-[Homo sapiens IL6R (récepteur de l'interleukine 6, IL-6R, CD126)], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-446) [Homo sapiens VH (IGHV3-9*01 (94.90%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*01 (117-446)], (219-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (96.80%) -IGKJ2*01) [6.3.9] (1'107') -IGKC*01 (108'-214')]; dimère (225-225'':228-228'')-bisdisulfure inmunoglobulina G1-kappa, anti-[Homo sapiens IL6R (receptor de la interleukina 6, IL-6R, CD126)], anticuerpo monoclonal de Homo sapiens; cadena pesada gamma1 (1-446) [Homo sapiens VH (IGHV3-9*01 (94.90%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*01 (117-446)], (219-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (96.80%) -IGKJ2*01) [6.3.9] (1'107') -IGKC*01 (108'-214')]; dímero (225-225'':228-228'')-bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada EVQLVESGGG LVQPGRSLRL SCAASRFTFD ISWNSGRIGY ADSVKGRFTI SRDNAENSLF DSFDIWGQGT MVTVSSASTK GPSVFPLAPS EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP PPSRDELTKN QVSLTCLVKG FYPSDIAVEW GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS VSASVGDRVT ITCRASQGIS ASSLESGVPS RFSGSGSGTD FTLTISSLQP GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSSPVTKSFN RGEC DYAMHWVRQA LQMNGLRAED SKSTSGGTAA LSSVVTVPSS PELLGGPSVF VEVHNAKTKP IEKTISKAKG ESNGQPENNY LHNHYTQKSL SWLAWYQQKP EDFASYYCQQ SVVCLLNNFY LSKADYEKHK PGKGLEWVSG TALYYCAKGR LGCLVKDYFP SLGTQTYICN LFPPKPKDTL REEQYNSTYR QPREPQVYTL KTTPPVLDSD SLSPGK 50 100 150 200 250 300 350 400 446
sarilumab
sarilumab
GKAPKLLIYG 50 ANSFPYTFGQ 100 PREAKVQWKV 150 VYACEVTHQG 200 214
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 143-199 260-320 366-424 22''-96'' 143''-199'' 260''-320'' 366''-424'' Intra-L 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L 219-214' 219''-214''' Inter-H-H 225-225'' 228-228'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 296, 296''
321
Recommended INN: List 68
WHO Drug Information, Vol. 26, No. 3, 2012
secretinum humanum secretin human
human peptide hormone secretin; L-histidyl-L-seryl-L-aspartylglycyl-L-threonyl-L-phenylalanylL-threonyl-L-seryl-L-glutamyl-L-leucyl-L-seryl-L-arginyl-L-leucylL-arginyl-L-glutamylglycyl-L-alanyl-Larginyl-L-leucyl-L-glutaminylL-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leucyl-L-valinamide sécrétine humaine hormone peptidique; L-histidyl-L-séryl-L-aspartylglycyl-L-thréonyl-L-phénylalanylL-thréonyl-L-séryl-L-glutamyl-L-leucyl-L-séryl-L-arginyl-L-leucylL-arginyl-L-glutamylglycyl-L-alanyl-L-arginyl-L-leucyl-L-glutaminylL-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leucyl-L-valinamide
sécrétine humaine
secretina humana
secretina humana, hormona peptídica; L-histidil-L-seril-L-aspartilglicil-L-treonil-L-fenilalanil-L-treonil-L-serilL-glutamil-L-leucil-L-seril-L-arginil-L-leucil-L-arginil-L-glutamilglicilL-alanil-L-arginil-L-leucil-L-glutaminil-L-arginil-L-leucil-L-leucilL-glutaminilglicil-L-leucil-L-valinamida C130 H220 N44 O40 HSDGTFTSEL SRLREGARLQ RLLQGLV 27
Modified residue / Résidu modifié / Residuo modificado V 27 valinamide H H3C CH3 O NH2 NH2
selisistatum selisistat sélisistat selisistat
rac-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide rac-6-chloro-2,3,4,9-tétrahydro-1H-carbazole-1-carboxamide rac-6-cloro-2,3,4,9-tetrahidro-1H-carbazol-1-carboxamida C13H13ClN2O H N Cl H O NH2 and enantiomer et énantiomère y enantiómero
setrobuvirum setrobuvir
N-(3-{(4aR,5S,8R,8aS)-1-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo1,2,4a,5,6,7,8,8a-octahydro-5,8-methanoquinolin-3-yl}-1,1-dioxo6 1,4-dihydro-1λ ,2,4-benzothiadiazin-7-yl)methanesulfonamide N-(3-{(4aR,5S,8R,8aS)-1-[(4-fluorophényl)méthyl]-4-hydroxy-2-oxo1,2,4a,5,6,7,8,8a-octahydro-5,8-méthanoquinoléin-3-yl}-1,1-dioxo6 1,4-dihydro-1λ ,2,4-benzothiadiazin-7-yl)méthanesulfonamide N-(3-{(4aR,5S,8R,8aS)-1-[(4-fluorofenil)metil]-4-hidroxi-2-oxo1,2,4a,5,6,7,8,8a-octahidro-5,8-metanoquinolin-3-il}-1,1-dioxo6 1,4-dihidro-1λ ,2,4-benzotiadiazin-7-il)metanosulfonamida
sétrobuvir
setrobuvir
322
WHO Drug Information, Vol. 26, No. 3, 2012
Recommended INN: List 68
C25H25FN4O6S2 F H
H
N
O H N
H
H
OH
N
S
O O
N H
O O S CH3
sevuparinum natricum sevuparin sodium
sodium salt of a low molecular mass heparin obtained by depolymerization through periodate oxidation of heparin from porcine intestinal mucosa, followed by reduction and mild acid hydrolysis of the product; the majority of the components have a 2-amino2-deoxy-D-glucopyranose derivative structure at both ends of their chain, the one at the reducing end can be substituted with threonic acid or erythronic acid; the relative average molecular mass range is approximately 7,500 daltons with about 90% ranging between 2,000 and 15,000 daltons; the degree of sulfation is 2 to 2.5 per disaccharidic unit sel sodique d'une héparine de basse masse moléculaire obtenue par dépolymérisation, au moyen d'une oxydation periodique, d'héparine de muqueuse intestinale de porc, suivi par une réduction et par une hydrolyse douce; la majorité des composants de la sévuparine sodique possèdent une structure 2-amino-2-déoxy-D-glucopyranose aux deux extrémités, la réductrice peut être substituée par un acide thréonique ou érythronique; la masse moléculaire relative moyenne est approximativement de 7500 daltons, et celles de 90% sont comprises entre 2000 à 15000; le degré de sulfatation est de 2 à 2,5 par unité disaccharide. sal sódica de una heparina de baja masa molecular obtenida por despolimerización, mediante oxidación periodica, de heparina de mucosa intestinal porcina, seguida de reducción e hidrólisis con ácido débil; la mayoría de los componentes de la sevuparina sódica tienen una estructura 2-amino-2-desoxi-D-glucopiranosa en los dos extremos, el reductor puede estar substituido con un ácido treónico o eritrónico; la masa molecular relativa media es aproximadamente de 7500 dalton, y con el 90% comprendido entre 2000 y 15000; el grado de sulfatación es de 2 a 2,5 por unidad de disacárido immunoglobulin scFv-scFv, anti-[Homo sapiens EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, KSA, KS1/4 antigen, M4S1, tumor antigen 17-1A, Ep-CAM, EpCAM, CD326)]/anti-[Homo sapiens CD3E (CD3 epsilon)], Mus musculus monoclonal antibody bispecific single chain; scFv anti-EPCAM [Mus musculus V-KAPPA (IGKV8-19*01 (98.00%)-IGKJ5*01 L126>I (112)) [12.3.9] (1-113) -15-mer tris(tetraglycyl-seryl) linker (114-128) -Mus musculus VH (IGHV154*01 (85.90%)-(IGHD)-IGHJ4*01, S123>T (243)) [8.8.14] (129248)] -5-mer tetraglycyl-seryl linker (249-253) -scFv anti-CD3E [humanized VH (Homo sapiens IGHV1-46*01 (82.50%)-(IGHD)IGHJ6*01) [8.8.12] (254-372) -18-mer linker (373-390) -V-KAPPA (Mus musculus IGKV4-59*01 (81.70%)-IGKJ1*01 L124>V (493) [5.3.9] (391-496)] -hexahistidine (497-502) 323
sévuparine sodique
sevuparina sódica
solitomabum # solitomab
Recommended INN: List 68
WHO Drug Information, Vol. 26, No. 3, 2012
solitomab
immunoglobuline scFv-scFv, anti-[Homo sapiens EPCAM (molécule d'adhésion des cellules épithéliales, transducteur 1 du signal calcium associé aux tumeurs, TACSTD1, protéine 2 associée aux tumeurs gastrointestinales, GA733-2, glycoprotéine épithéliale 2, EGP-2, KSA, antigène KS1/4, M4S1, antigène tumoral 17-1A, Ep-CAM, EpCAM, CD326)]/anti-[Homo sapiens CD3E (CD3 epsilon)], Mus musculus anticorps monoclonal bispécifique à chaîne unique; scFv anti-EPCAM [Mus musculus V-KAPPA (IGKV8-19*01 (98.00%)-IGKJ5*01 L126>I (112)) [12.3.9] (1-113) -15-mer tris(tétraglycyl-séryl) linker (114-128) -Mus musculus VH (IGHV154*01 (85.90%)-(IGHD)-IGHJ4*01, S123>T (243)) [8.8.14] (129248)] -5-mer tétraglycyl-séryl linker (249-253) -scFv anti-CD3E [VH humanisé (Homo sapiens IGHV1-46*01 (82.50%)-(IGHD)-IGHJ6*01) [8.8.12] (254-372) -18-mer linker (373-390) -V-KAPPA (Mus musculus IGKV4-59*01 (81.70%)-IGKJ1*01 L124>V (493) [5.3.9] (391-496)] -hexahistidine (497-502) inmunoglobulina scFv-scFv, anti-[EPCAM de Homo sapiens (molécula de adhesión de células epiteliales, transductor 1 de la señal de calcio asociado a tumores, TACSTD1, proteina 2 asociada a tumores gastrointestinales, GA733-2, glicoproteina epitelial 2, EGP-2, KSA, antígeno KS1/4, M4S1, antígeno tumoral 17-1A, EpCAM, EpCAM, CD326)]/anti-[Homo sapiens CD3E (CD3 epsilon)], anticuerpo monoclonal biespecifico monocatenario de Mus musculus; scFv anti-EPCAM [Mus musculus V-KAPPA (IGKV8-19*01 (98.00%)-IGKJ5*01 L126>I (112)) [12.3.9] (1-113) -15-mer tris(tetraglicil-seril) conector (114-128) -Mus musculus VH (IGHV154*01 (85.90%)-(IGHD)-IGHJ4*01, S123>T (243)) [8.8.14] (129248)] -5-mer tetraglicil-seril conector (249-253) -scFv anti-CD3E [VH humanizado (Homo sapiens IGHV1-46*01 (82.50%)-(IGHD)IGHJ6*01) [8.8.12] (254-372) -18-mer conector (373-390) -V-KAPPA (Mus musculus IGKV4-59*01 (81.70%)-IGKJ1*01 L124>V (493) [5.3.9] (391-496)] -hexahistidina (497-502) ELVMTQSPSS KLLIYWASTR PLTFGAGTKL CKASGYAFTN ADKSSSTAYM GGSDVQLVQS IGYINPSRGY RYYDDHYCLD LSLSPGERAT FSGSGSGTDY HH LTVTAGEKVT ESGVPDRFTG EIKGGGGSGG YWLGWVKQRP QLSSLTFEDS GAEVKKPGAS TNYADSVKGR YWGQGTTVTV LSCRASQSVS SLTINSLEAE MSCKSSQSLL SGSGTDFTLT GGSGGGGSEV GHGLEWIGDI AVYFCARLRN VKVSCKASGY FTITTDKSTS SSGEGTSTGS YMNWYQQKPG DAATYYCQQW NSGNQKNYLT ISSVQAEDLA QLLEQSGAEL FPGSGNIHYN WDEPMDYWGQ TFTRYTMHWV TAYMELSSLR GGSGGSGGAD KAPKRWIYDT SSNPLTFGGG WYQQKPGQPP VYYCQNDYSY VRPGTSVKIS EKFKGKATLT GTTVTVSSGG RQAPGQGLEW SEDTATYYCA DIVLTQSPAT SKVASGVPAR TKVEIKHHHH 50 100 150 200 250 300 350 400 450 500 502
solitomab
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-chain 23-94 151-225 275-349 413-477 N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 305 (but Pro in 306)
sovaprevirum sovaprevir
(2S,4R)-1-[(2S)-2-tert-butyl-4-oxo-4-(piperidin-1-yl)butanoyl]N-{(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]2-ethenylcyclopropyl}-4-[(7-methoxy-2-phenylquinolin4-yl)oxy]pyrrolidine-2-carboxamide
324
WHO Drug Information, Vol. 26, No. 3, 2012
Recommended INN: List 68
sovaprévir
(2S,4R)-1-[(2S)-2-tert-butyl-4-oxo-4-(pipéridin-1-yl)butanoyl]N-{(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]2-éthénylcyclopropyl}-4-[(7-méthoxy-2-phénylquinoléin4-yl)oxy]pyrrolidine-2-carboxamide (2S,4R)-1-[(2S)-2-terc-butil-4-oxo-4-(piperidin-1-il)butanoil]N-{(1R,2S)-1-[(ciclopropanosulfonil)carbamoil]-2-etenilciclopropil}4-[(7-metoxi-2-fenilquinolin-4-il)oxi]pirrolidina-2-carboxamida C43H53N5O8S
sovaprevir
H3CO
N
H 3C O N
CH3 CH3 H O N
H
O H N O O O S N H CH2
H
O H
sutezolidum sutezolid sutézolid sutezolid
N-({(5S)-3-[3-fluoro-4-(thiomorpholin-4-yl)phenyl]-2-oxo1,3-oxazolan-5-yl}methyl)acetamide N-({(5S)-3-[3-fluoro-4-(thiomorpholin-4-yl)phényl]-2-oxo1,3-oxazolidin-5-yl}méthyl)acétamide N-({(5S)-3-[3-fluoro-4-(tiomorfolin-4-il)fenil]-2-oxo-1,3-oxazolan5-il}metil)acetamida C16H20FN3O3S H H N O N S O N O F
H 3C
tanzisertibum tanzisertib tanzisertib tanzisertib
(1r,4r)-4-({9-[(3S)-oxolan-3-yl]-8-[(2,4,6-trifluorophenyl)amino]9H-purin-2-yl}amino)cyclohexan-1-ol (1r,4r)-4-({9-[(3S)-oxolan-3-yl]-8-[(2,4,6-trifluorophényl)amino]9H-purin-2-yl}amino)cyclohexan-1-ol (1r,4r)-4-({9-[(3S)-oxolan-3-il]-8-[(2,4,6-trifluorfenil)amino]-9H-purin2-il}amino)ciclohexan-1-ol
325
Recommended INN: List 68
WHO Drug Information, Vol. 26, No. 3, 2012
C21H23F3N6O2 F H HO N H H N N H O F N NH N F
tavaborolum tavaborole tavaborole tavaborol
5-fluoro-2,1-benzoxaborol-1(3H)-ol 5-fluoro-2,1-benzoxaborol-1(3H)-ol 5-fluoro-2,1-benzoxaborol-1(3H)-ol C7H6BFO2 OH B O F
tedatioxetinum tedatioxetine tédatioxétine tedatioxetina
4-{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine 4-{2-[(4-méthylphényl)sulfanyl]phényl}pipéridine 4-{2-[(4-metilfenil)sulfanil]fenil}piperidina C18H21NS
S H3C
NH
tipiracilum tipiracil tipiracil tipiracilo
5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine2,4-(1H,3H)-dione 5-chloro-6-[(2-iminopyrrolidin-1-yl)méthyl]pyrimidine2,4-(1H,3H)-dione 5-cloro-6-[(2-iminopirrolidin-1-il)metil]pirimidina-2,4-(1H,3H)-diona C9H11ClN4O2 O HN N HN Cl NH O
326
WHO Drug Information, Vol. 26, No. 3, 2012
Recommended INN: List 68
tirasemtivum tirasemtiv tirasemtiv tirasemtiv
6-ethynyl-1-(pentan-3-yl)-2H-imidazo[4,5-b]pyrazin-2-one 6-éthynyl-1-(pentan-3-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyrazin2-one 6-etinil-1-(pentan-3-il)-2H-imidazo[4,5-b]pirazin-2-ona C12H14N4O H3C HC N N N N H CH3 O
tozadenantum tozadenant tozadénant tozadenant
4-hydroxy-N-[4-methoxy-7-(morpholin-4-yl)-1,3-benzothiazol-2-yl]4-methylpiperidine-1-carboxamide 4-hydroxy-N-[4-méthoxy-7-(morpholin-4-yl)-1,3-benzothiazol-2-yl]4-méthylpipéridine-1-carboxamide 4-hidroxi-N-[4-metoxi-7-(morfolin-4-il)-1,3-benzotiazol-2-il]4-metilpiperidina-1-carboxamida C19H26N4O4S O N S NH N OCH3
O N
CH3 OH
trebananibum # trebananib
immunoglobulin G1 Fc fragment fused with two synthetic polypeptides that bind the Homo sapiens ANGPT2 (angiopoietin 2); methionyl (1) -gamma1 heavy chain fragment (2-228) [Homo sapiens IGHG1*01 hinge (EPKSC 1-5>del) (2-11), CH2 (12-121), CH3 (122-228)] fused, at the C-terminal end, with a synthetic polypeptide that comprises two 14-mer amino acid repeats that bind angiopoietin 2 (229-287) [linker (229-235) -14-mer (236-249) -linker (250-271) -14-mer (272-285) -leucyl-glutamate]; (7-7':10-10')bisdisulfide dimer immunoglobuline G1 fragment Fc fusionné à deux polypeptides synthétiques qui se lient à l'Homo sapiens ANGPT2 (angiopoïétine 2); méthionyl (1) -fragment de chaîne gamma1 (2-228) [Homo sapiens IGHG1*01 charnière (EPKSC 1-5>del) (2-11), CH2 (12-121), CH3 (122-228)] fusionné, à l'extrémité C-terminale, à un polypeptide synthétique qui comprend deux motifs répétés de 14 acides aminés qui se lient à l'angiopoïétine 2 (229-287) [linker (229-235) -14-mer (236-249) -linker (250-271) -14-mer (272-285) -leucyl-glutamate]; dimère (7-7':10-10')-bisdisulfure
trébananib
327
Recommended INN: List 68
WHO Drug Information, Vol. 26, No. 3, 2012
trebananib
inmunoglobulina G1 fragmento Fc fusionado con dos polipéptidos sintéticos que se unen a la ANGPT2 (angiopoyetina 2) de Homo sapiens; metionil (1) -fragmento de cadena gamma1 (2-228) [Homo sapiens IGHG1*01 bisagra (EPKSC 1-5>del) (2-11), CH2 (12-121), CH3 (122-228)] fusionada con el extremo C-terminal de un polipéptido sintético que comprende dos secuencias repetidas de 14 aminoácidos que se unen a la angiopoyetina 2 (229-287) [conector (229-235) -14-mer (236-249) -conector (250-271) -14-mer (272-285) -leucil-glutamato]; dímero (7-7':10-10')-bisdisulfuro MDKTHTCPPC DPEVKFNWYV KCKVSNKALP KGFYPSDIAV GNVFSCSVMH SGSATGGSGS PAPELLGGPS DGVEVHNAKT APIEKTISKA EWESNGQPEN EALHNHYTQK TASSGSGSAT VFLFPPKPKD KPREEQYNST KGQPREPQVY NYKTTPPVLD SLSLSPGKGG HQEECEWDPW TLMISRTPEV YRVVSVLTVL TLPPSRDELT SDGSFFLYSK GGGAQQEECE TCEHMLE TCVVVDVSHE HQDWLNGKEY KNQVSLTCLV LTVDKSRWQQ WDPWTCEHMG 50 100 150 200 250 287
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-chain 42-102 148-206 239-246 275-282 42'-102' 148'-206' 239'-246' 275'-282' Inter-chains 7-7' 10-10' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 78, 78'
trelagliptinum trelagliptin trélagliptine trelagliptina
2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo3,4-dihydropyrimidin-1(2H)-yl}methyl)-4-fluorobenzonitrile 2-({6-[(3R)-3-aminopipéridin-1-yl]-3-méthyl-2,4-dioxo3,4-dihydropyrimidin-1(2H)-yl}méthyl)-4-fluorobenzonitrile 2-({6-[(3R)-3-aminopiperidin-1-il]-3-metil-2,4-dioxo3,4-dihidropirimidin-1(2H)-il}metil)-4-fluorobenzonitrilo C18H20FN5O2 H H2N N N O N CH3 O F CN
umeclidinii bromidum umeclidinium bromide bromure d’uméclidinium bromuro de umeclidinio
1-{2-[(benzyl)oxy]ethyl}4-[hydroxydi(phenyl)methyl]1-azabicyclo[2.2.2]octan-1-ium bromide bromure de 1-{2-[(benzyl)oxy]éthyl}-4-[hydroxydi(phényl)méthyl]1-azabicyclo[2.2.2]octanium bromuro de 1-{2-[(bencil)oxi]etil}4-[hidroxidi(fenil)metil]1-azabiciclo[2.2.2]octan-1-io
328
WHO Drug Information, Vol. 26, No. 3, 2012
Recommended INN: List 68
C29H34BrNO2
N OH O
Br
vapendavirum vapendavir vapendavir vapendavir
3-ethoxy-6-{2-[1-(6-methylpyridazin-3-yl)piperidin-4-yl]ethoxy}1,2-benzoxazole 3-éthoxy-6-{2-[1-(6-méthylpyridazin-3-yl)pipéridin-4-yl]éthoxy}1,2-benzoxazole 3-etoxi-6-{2-[1-(6-metilpiridazin-3-il)piperidin-4-il]etoxi}1,2-benzoxazol C21H26N4O3 H 3C N N N O O N O
CH3
vonoprazanum vonoprazan vonoprazan vonoprazán
1-[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrol-3-yl]N-methylmethanamine 1-[5-(2-fluorophényl)-1-(pyridine-3-sulfonyl)-1H-pyrrol-3-yl]N-méthylméthanamine 1-[5-(2-fluorofenil)-1-(piridina-3-sulfonil)-1H-pirrol-3-il]N-metilmetanamina C17H16FN3O2S
O O S N
N
CH3 F NH
vortioxetinum vortioxetine vortioxétine vortioxetina
1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine 1-{2-[(2,4-diméthylphényl)sulfanyl]phényl}pipérazine 1-{2-[(2,4-dimetilfenil)sulfanil]fenil}piperazina
329
Recommended INN: List 68
WHO Drug Information, Vol. 26, No. 3, 2012
C18H22N2S
N S H3C CH3 NH
330
WHO Drug Information, Vol. 26, No. 3, 2012
Recommended INN: List 68
AMENDMENTS TO PREVIOUS LISTS MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES MODIFICACIONES A LAS LISTAS ANTERIORES Recommended International Non Proprietary Names (Rec. INN): List 17 (Chronicle of the WHO, 1977, Vol. 31, No. 10) p. 7 oxitropii bromidum oxitropium bromide
replace the description and the structure by the following ones (1R,2R,4S,5S,7s,9s)-9-ethyl-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}2,4 9-methyl-3-oxa-9-azoniatricyclo[3.3.1.0 ]nonane bromide H O H O H OH H N CH3 CH3 H O Br H
Dénominations communes internationales recommandées (DCI Rec.): Liste 17 (Chronique de l'OMS, Vol. 31, No. 10, 1977) p. 7 oxitropii bromidum bromure d’oxitropium
remplacer la description et la structure par les suivantes bromure de (1R,2R,4S,5S,7s,9s)-9-éthyl-7-{[(2S)-3-hydroxy2,4 2-phénylpropanoyl]oxy}-9-méthyl-3-oxa-9-azoniatricyclo[3.3.1.0 ]nonane H O H O H OH H N CH3 CH3 H O Br H
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 17 (Crónica de la OMS, Vol. 31, No. 10, 1977) p. 7 oxitropii bromidum bromuro de oxitropio
sustitúyase la descripción y la estructura por las siguientes bromuro de (1R,2R,4S,5S,7s,9s)-9-etil-7-{[(2S)-2-fenil-3-hidroxipropanoil]oxi}2,4 9-metil-3-oxa-9-azoniatriciclo[3.3.1.0 ]nonano H O H O H OH H N CH3 CH3 H O Br H
331
Recommended INN: List 68
WHO Drug Information, Vol. 26, No. 3, 2012
Recommended International Non Proprietary Names (Rec. INN): List 58 Dénominations communes internationales recommandées (DCI Rec.): Liste 58 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 58 (WHO Drug Information, Vol. 21, No. 3, 2007)
p. 260 & 261
ulipristalum ulipristal ulipristal ulipristal
replace the structure by the following remplacer la structure par la suivante sustitúyase la estructura por la siguiente CH3 H3C N H H H O O CH3 CH3 OH
Recommended International Non Proprietary Names (Rec. INN): List 60 Dénominations communes internationales recommandées (DCI Rec.): Liste 60 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 60 (WHO Drug Information, Vol. 22, No. 3, 2008) p. 229 conestatum alfa # conestat alfa conestat alfa conestat alfa
replace the structure by the following remplacer la structure par la suivante sustitúyase la estructura por la siguiente NPNATSSSSQ NSATKITANT CPGPVTLCSD SIASLLTQVL QIFHSPDLAI KISRLLDSLP PMMNSKKYPV ALSPSVFKAI YDLNLCGLTE VQQPFLFVLW DPESLQDRGE TDEPTTQPTT LESHSTEAVL LGAGENTKTN RDTFVNASRT SDTRLVLLNA AHFIDQTLKA MEKLEMSKFQ DPDLQVSAMQ DQQHKFPVFM GKVATTVISK EPTTQPTIQP GDALVDFSLK LESILSYPKD LYSSSPRVLS IYLSAKWKTT KVGQLQLSHN PTLLTLPRIK HQTVLELTET GRVYDPRA MLFVEPILEV TQPTTQLPTD LYHAFSAMKK FTCVHQALKG NNSDANLELI FDPKKTRMEP LSLVILVPQN VTTSQDMLSI GVEAAAASAI SSLPTTNSTT SPTQPTTGSF VETNMAFSPF FTTKGVTSVS NTWVAKNTNN FHFKNSVIKV LKHRLEDMEQ MEKLEFFDFS SVARTLLVFE 50 100 150 200 250 300 350 400 450 478
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 101-406 108-183 Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación Asn-3 Thr-26 Ser-42 Asn-47 Thr-49 Asn-59 Thr-61 Thr-66 Thr-70 Thr-74 Asn-216 Asn-231 Asn-330
Recommanded International Non Proprietary Names (Rec. INN): List 61 Denominations communes internationales recommandées (DCI Rec.): Liste 61 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 61 (WHO Drug Information, Vol. 23, No. 1, 2009)
p. 67
macitentanum macitentan
replace the chemical name by the following N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy} pyrimidin-4-yl]-N'-propylsulfuric diamide
332
WHO Drug Information, Vol. 26, No. 3, 2012
Recommended INN: List 68
Recommanded International Non Proprietary Names (Rec. INN): List 62 Denominations communes internationales recommandées (DCI Rec.): Liste 62 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 62 (WHO Drug Information, Vol. 23, No. 3, 2009) p. 263 & 264 solanezumabum # solanezumab solanezumab solanezumab replace the description and the structure by the following ones remplacer la description et la structure par les suivantes sustitúyase la descripción y la estructura por las siguientes immunoglobulin G1-kappa, anti-[Homo sapiens amyloid-beta (Abeta) peptide soluble monomer], humanized monoclonal antibody; gamma1 heavy chain [humanized VH (Homo sapiens IGHV3-23*04 (87.60%) (IGHD)-IGHJ4*01) [8.8.5] (1-112) -Homo sapiens IGHG1*01 (113-442)], (215-219')disulfide with kappa light chain (1’-219’) [humanized V-KAPPA (Homo sapiens IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'219')]; (221-221":224-224")-bisdisulfide dimer immunoglobuline G1-kappa, anti-[Homo sapiens amyloïde-bêta (Abeta) peptide monomère soluble], anticorps monoclonal humanisé; chaîne lourde gamma1 [VH humanisé (Homo sapiens IGHV3-23*04 (87.60%) (IGHD)-IGHJ4*01) [8.8.5] (1-112) -Homo sapiens IGHG1*01 (113-442)], (215-219')disulfure avec la chaîne légère kappa (1’-219’) [V-KAPPA humanisé (Homo sapiens IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'219')]; dimère (221-221":224-224")-bisdisulfure inmunoglobulina G1-kappa, anti-[péptido amiloide-beta (Abeta) monomèrico soluble de Homo sapiens], anticuerpo monoclonal humanizado; cadena pesada gamma1 [VH humanizado (Homo sapiens IGHV3-23*04 (87.60%) (IGHD)-IGHJ4*01) [8.8.5] (1-112) -Homo sapiens IGHG1*01 (113-442)], (215-219')disulfuro con la cadena ligera kappa (1’-219’) [V-KAPPA humanizado (Homo sapiens IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dímero (221-221":224-224")-bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada EVQLVESGGG LVQPGGSLRL SCAASGFTFS INSVGNSTYY PDTVKGRFTI SRDNAKNTLY YWGQGTLVTV SSASTKGPSV FPLAPSSKST VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV PSNTKVDKKV EPKSCDKTHT CPPCPAPELL TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH LTVLHQDWLN GKEYKCKVSN KALPAPIEKT DELTKNQVSL TCLVKGFYPS DIAVEWESNG LYSKLTVDKS RWQQGNVFSC SVMHEALHNH Light chain / Chaîne légère / Cadena ligera DVVMTQSPLS LPVTLGQPAS ISCRSSQSLI LLIYKVSNRF SGVPDRFSGS GSGTDFTLKI WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL VQWKVDNALQ SGNSQESVTE QDSKDSTYSL VTHQGLSSPV TKSFNRGEC RYSMSWVRQA LQMNSLRAED SGGTAALGCL VTVPSSSLGT GGPSVFLFPP NAKTKPREEQ ISKAKGQPRE QPENNYKTTP YTQKSLSLSP YSDGNAYLHW SRVEAEDVGV KSGTASVVCL SSTLTLSKAD PGKGLELVAQ TAVYYCASGD VKDYFPEPVT QTYICNVNHK KPKDTLMISR YNSTYRVVSV PQVYTLPPSR PVLDSDGSFF GK 50 100 150 200 250 300 350 400 442
FLQKPGQSPR 50 YYCSQSTHVP 100 LNNFYPREAK 150 YEKHKVYACE 200 219
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 139-195 256-316 362-420 22''-96'' 139''-195'' 256''-316'' 362''-420'' Intra-L 23'-93' 139'-199' 23'''-93''' 139'''-199''' Inter-H-L 215-219' 215''-219''' Inter-H-H 221-221'' 224-224'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H VH CDR2-IMGT N63: 56, 56'' H CH2 N84.4: 292, 292''
333
Recommended INN: List 68
WHO Drug Information, Vol. 26, No. 3, 2012
Recommended International Non Proprietary Names (Rec. INN): List 64 Dénominations communes internationales recommandées (DCI Rec.): Liste 64 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 64 (WHO Drug Information, Vol. 23, No. 4, 2009) p. 264 & 265 dalotuzumabum # dalotuzumab dalotuzumab dalotuzumab replace the description and the structure by the following ones remplacer la description et la structure par les suivantes sustitúyase la descripción y la estructura por las siguientes immunoglobulin G1-kappa, anti-[Homo sapiens IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221], humanized monoclonal antibody; gamma1 heavy chain (1-447) [humanized VH (Homo sapiens IGHV4-61*08 (86.90%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -Homo sapiens IGHG1*03 (118447)], (220-219')-disulfide with kappa light chain (1’-219’) [humanized V-KAPPA (Homo sapiens IGKV2-29*03 (84.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; (226-226":229-229")-bisdisulfide dimer immunoglobuline G1-kappa, anti-[Homo sapiens IGF1R (récepteur du facteur de croissance 1 analogue à l’insuline (IGF1-R, IGF-1R, CD221)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-447) [VH humanisé (Homo sapiens IGHV4-61*08 (86.90%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -Homo sapiens IGHG1*03 (118447)], (220-219')-disulfure avec la chaîne légère kappa (1’-219’) [V-KAPPA humanisé (Homo sapiens IGKV2-29*03 (84.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (226-226":229-229")-bisdisulfure inmunoglobulina G1-kappa, anti-[Homo sapiens IGF1R (receptor del factor de crecimiento similar a la insulina 1 (IGF1-R, IGF-1R, CD221)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-447) [VH humanizado (Homo sapiens IGHV4-61*08 (86.90%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -Homo sapiens IGHG1*03 (118447)], (220-219')-disulfuro con la cadena ligera kappa (1’-219’) [V-KAPPA humanizado (Homo sapiens IGKV2-29*03 (84.00%) -IGKJ1*01) [11.3.9] (1'-112') Homo sapiens IGKC*01 (113'-219')]; dímero (226-226":229-229")-bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada QVQLQESGPG LVKPSETLSL TCTVSGYSIT YISYDGTNNY KPSLKDRVTI SRDTSKNQFS RVFFDYWGQG TLVTVSSAST KGPSVFPLAP PEPVTVSWNS GALTSGVHTF PAVLQSSGLY NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP LMISRTPEVT CVVVDVSHED PEVKFNWYVD RVVSVLTVLH QDWLNGKEYK CKVSNKALPA LPPSREEMTK NQVSLTCLVK GFYPSDIAVE DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE Light chain / Chaîne légère / Cadena ligera DIVMTQSPLS LPVTPGEPAS ISCRSSQSIV LLIYKVSNRL YGVPDRFSGS GSGTDFTLKI WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL VQWKVDNALQ SGNSQESVTE QDSKDSTYSL VTHQGLSSPV TKSFNRGEC GGYLWNWIRQ LKLSSVTAAD SSKSTSGGTA SLSSVVTVPS APELLGGPSV GVEVHNAKTK PIEKTISKAK WESNGQPENN ALHNHYTQKS HSNGNTYLQW SRVEAEDVGV KSGTASVVCL SSTLTLSKAD PPGKGLEWIG TAVYYCARYG ALGCLVKDYF SSLGTQTYIC FLFPPKPKDT PREEQYNSTY GQPREPQVYT YKTTPPVLDS LSLSPGK 50 100 150 200 250 300 350 400 447
YLQKPGQSPQ 50 YYCFQGSHVP 100 LNNFYPREAK 150 YEKHKVYACE 200 219
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 144-200 261-321 367-425 22''-96'' 144''-200'' 261''-321'' 367''-425'' Intra-L 23'-93' 139'-199' 23'''-93''' 139'''-199''' Inter-H-L 220-219' 220''-219''' Inter-H-H 226-226'' 229-229'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4 297, 297''
334
WHO Drug Information, Vol. 26, No. 3, 2012
Recommended INN: List 68
Recommended International Non Proprietary Names (Rec. INN): List 67 Dénominations communes internationales recommandées (DCI Rec.): Liste 67 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 67 (WHO Drug Information, Vol. 26, No. 1, 2012)
p. 70
lipegfilgrastimum # lipegfilgrastim lipegfilgrastim lipegfilgrastim
replace the description and the structure by the following ones remplacer la description et la structure par les suivantes sustitúyase la descripción y la estructura por las siguientes pegylated granulocyte colony stimulating factor (human short isoform); 3.137 -[{3,5-dideoxy-5-[(N-{[ω-methoxypoly(oxyethylene)]carbonyl}glycyl)amino]O D-glycero-α-D-galacto-non-2-ulopyranosylonic acid}-(2→6)-2-(acetylamino)-2-deoxyα-D-galactopyranosyl]-des-(37-39)-[1-methionine]human granulocyte colony-stimulating factor (G-CSF, pluripoietin) facteur de stimulation de colonie de granulocytes (isoforme court humain) pégylé; 3.137 O -[{acide 3,5-didéoxy-5-[(N-{[ω-méthoxypoly(oxyéthylène)]carbonyl}glycyl)amino]D-glycéro-α-D-galacto-non-2-ulopyranosylonique}-(2→6)-2-(acétylamino)-2-déoxyα-D-galactopyranosyl]-dès-(37-39)-[1-méthionine]facteur humain de stimulation de colonie de granulocytes (G-CSF, pluripoïétine) factor de estimulacin de colonías de granulocitos (isoformo corto humano) pegilado; 3.137 O -[{acído 3,5-didesoxi-5-[(N-{[ω-metoxipoli(oxietileni)]carbonil}glicil)amino]D-glicero-α-D-galacto-non-2-ulopiranosilonico}-(2→6)-2-(acetilamino)-2-desoxiα-D-galactopiranosil]-dès-(37-39)-[1-metionina]factor humano de estimulación de colonías de granulocitos (G-CSF, pluripoyetina) MTPLGPASSL LVLLGHSLGI PELGPTLDTL RAGGVLVASH PQSFLLKCLE PWAPLSSCPS QLDVADFATT LQSFLEVSYR QVRKIQGDGA ALQEKL---C ATYKLCHPEE 50 QALQLAGCLS QLHSGLFLYQ GLLQALEGIS 100 IWQQMEELGM APALQPTQGA MPAFASAFQR 150 VLRHLAQP 178
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 40-46 68-78 Modified residues / Résidu modifié / Residuo modificado HO T 137 PEG-Gly-Neu-GalNac-Thr H3C O O n
OH HO H O CO2H O O HO O OH HO O CH3 NH O H2 N CH3 H CO2H
H N O
HN
335
Recommended INN: List 68
WHO Drug Information, Vol. 26, No. 3, 2012
# Electronic structure available on Mednet: http://mednet.who.int/ # Structure électronique disponible sur Mednet: http://mednet.who.int/ # Estructura electrónica disponible en Mednet: http://mednet.who.int/
Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances will be reproduced in proposed INN lists only. Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées. El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.
336